339 related articles for article (PubMed ID: 32564612)
41. CD171 Multi-epitope peptide design based on immuno-informatics approach as a cancer vaccine candidate for glioblastoma.
Mohammadzadeh Hosseini Moghri SAH; Mahmoodi Chalbatani G; Ranjbar M; Raposo C; Abbasian A
J Biomol Struct Dyn; 2023 Feb; 41(3):1028-1040. PubMed ID: 36617427
[TBL] [Abstract][Full Text] [Related]
42. Personalized peptide vaccine for treatment of advanced cancer.
Sasada T; Yamada A; Noguchi M; Itoh K
Curr Med Chem; 2014; 21(21):2332-45. PubMed ID: 24524766
[TBL] [Abstract][Full Text] [Related]
43. Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
Singh J; Malik D; Raina A
Vaccine; 2021 Feb; 39(7):1087-1095. PubMed ID: 33478787
[TBL] [Abstract][Full Text] [Related]
44. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
45. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.
Foy KC; Miller MJ; Overholser J; Donnelly SM; Nahta R; Kaumaya PT
Oncoimmunology; 2014 Nov; 3(11):e956005. PubMed ID: 25941587
[TBL] [Abstract][Full Text] [Related]
46. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.
Mohit E; Hashemi A; Allahyari M
Expert Rev Clin Immunol; 2014 Jul; 10(7):927-61. PubMed ID: 24867051
[TBL] [Abstract][Full Text] [Related]
47. Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.
Stephens AJ; Burgess-Brown NA; Jiang S
Front Immunol; 2021; 12():696791. PubMed ID: 34276688
[TBL] [Abstract][Full Text] [Related]
48. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.
Renaudet O; Dasgupta G; Bettahi I; Shi A; Nesburn AB; Dumy P; BenMohamed L
PLoS One; 2010 Jun; 5(6):e11216. PubMed ID: 20574522
[TBL] [Abstract][Full Text] [Related]
49. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.
Fernández IM; Harmsen M; Benaissa-Trouw BJ; Stuij I; Puyk W; Meloen RH; Snippe H; Kraaijeveld CA
Vaccine; 1998 Oct; 16(16):1531-6. PubMed ID: 9711800
[TBL] [Abstract][Full Text] [Related]
50. Peptide vaccines in breast cancer: The immunological basis for clinical response.
Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
[TBL] [Abstract][Full Text] [Related]
51. A novel method for enhancement of peptide vaccination utilizing T-cell epitopes from conventional vaccines.
Yano A; Miwa Y; Kanazawa Y; Ito K; Makino M; Imai S; Hanada N; Nisizawa T
Vaccine; 2013 Mar; 31(11):1510-5. PubMed ID: 23318151
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
53. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T
J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930
[TBL] [Abstract][Full Text] [Related]
54. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
[TBL] [Abstract][Full Text] [Related]
55. Harnessing Bioinformatics for Designing a Novel Multiepitope Peptide Vaccine Against Breast Cancer.
Mahmoodi S; Nezafat N; Barzegar A; Negahdaripour M; Nikanfar AR; Zarghami N; Ghasemi Y
Curr Pharm Biotechnol; 2016; 17(12):1100-1114. PubMed ID: 27633889
[TBL] [Abstract][Full Text] [Related]
56. B epitope multiplicity and B/T epitope orientation influence immunogenicity of foot-and-mouth disease peptide vaccines.
Blanco E; Cubillos C; Moreno N; Bárcena J; de la Torre BG; Andreu D; Sobrino F
Clin Dev Immunol; 2013; 2013():475960. PubMed ID: 24454475
[TBL] [Abstract][Full Text] [Related]
57. In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.
Herrera LRM
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2297-2306. PubMed ID: 32856858
[TBL] [Abstract][Full Text] [Related]
58. Designing B-Cell Epitopes for Immunotherapy and Subunit Vaccines.
Singh H; Gupta S; Gautam A; Raghava GP
Methods Mol Biol; 2015; 1348():327-40. PubMed ID: 26424284
[TBL] [Abstract][Full Text] [Related]
59. Synthetic B- and T-cell epitope peptides of porcine reproductive and respiratory syndrome virus with Gp96 as adjuvant induced humoral and cell-mediated immunity.
Chen C; Li J; Bi Y; Yang L; Meng S; Zhou Y; Jia X; Meng S; Sun L; Liu W
Vaccine; 2013 Apr; 31(14):1838-47. PubMed ID: 23395588
[TBL] [Abstract][Full Text] [Related]
60. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
